Loading stock data…
$23.86-0.06 (-0.23%)
SpyGlass Pharma, Inc.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$21.97M↓ | -$15.41M↓ | -$13.63M↓ | -$11.10M↓ | -$9.30M |
| Net Income | -$19.86M↓ | -$13.82M↓ | -$12.56M↓ | -$9.82M↓ | -$8.68M |
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and pr...